Abstract
Radium223 dichloride (Xofigo®) recently granted marketing authorization (MA) in Europe for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease. The development of this new metabolic radiotherapy in our department started with temporary authorizations for use and then under the MA, led us to evaluate its clinicobiological safety and efficacy in our patients. We have also proposed a monitoring of the therapeutic efficacy with 18FNa PET-CT imaging. The treatment was particularly well tolerated and a clear analgesic effect was observed, especially after the first injections. The identification of a therapeutic efficacy through biological parameters and imaging has been more problematic. These results led us to discuss a more rigorous selection of patients eligible for this type of treatment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
